Smith & Nephew plc (SNN) Fair Value 2026

SNN · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.7 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (7/100)

Quick Summary — As of 2026-08-27, Smith & Nephew plc (SNN) trades at $29.13, versus a $31.14 median fair value across its 9 active models — 6.9% above the current price. QOC: 8.7/10. Value Trap Risk: 7/100 (SAFE). 9/13 models active. Within that set, the Bayesian DCF component alone returns $34.69.

Key Facts

Ticker
SNN
Price
$29.13
Quality Score
8.7/10
Value Trap Risk
7/100
Models Active
9/13
Last Updated
Strength: Bayesian DCF suggests +19.1% upside with 62% confidence
Risk: Majority of models suggest overvaluation

Is Smith & Nephew plc (SNN) Undervalued or Overvalued in 2026?

According to CirclFi’s 9-model valuation engine, Smith & Nephew plc (SNN) appears fairly valued as of : the median of 9 independent fair value estimates is $31.14, within 6.9% of the current price of $29.13. Estimates range from $8.58 to $72.93. SNN scores 8.7/10 on fundamental quality and 7/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. SNN’s +6.9% gap is narrower than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Smith & Nephew plc Stock in 2026? →

What Fair Value Does Each Model Give SNN?

9 Intrinsic Value Models vs. Current Price ($29.13)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $34.69 +19.1%
Intrinsic · High Conviction
 $15.65 -46.3%
Ensemble · Low Conviction
 $26.48 -9.1%
Intrinsic · High Conviction
 $18.83 -35.4%
Unlock the Full Matrix

Access 5 additional models including Markov DDM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is SNN's Fair Value Range?

Spread across 9 independent models · $8.58 to $72.93

CirclFi's 9 active models place Smith & Nephew plc (SNN) between $8.58 and $72.93 per share, a spread of 207% of the median. The median of that range — $31.14 — is the fair value CirclFi publishes for SNN, against a current price of $29.13.

Low · Markov DDMHigh · Regime Cross
$8.58median $31.14$72.93
Where the range comes from
Most bearish modelMarkov DDM$8.58
Most bullish modelRegime Cross-Sectional$72.93
Model agreement5 bullish · 4 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for SNN. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on SNN, not a CirclFi price target. How each model works →

What Is Smith & Nephew plc (SNN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Smith & Nephew plc's intrinsic value is estimated at $31.14, suggesting a +6.9% median upside from the current price of $29.13. While 5 models see room for appreciation, model agreement is not unanimous as 4 models flag potential overvaluation. Model dispersion is worth noting: Regime Cross targets $72.93 (+150.4%), versus Markov DDM at $8.58 (-70.6%). This +220.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SNN?

9 of 13 models are currently active for SNN. Of these, 5 models suggest upside while 4 models suggest overvaluation. Taken together, their median fair value for SNN is $31.14 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $34.69 on its own, implying +19.1% upside from the current price. See which stocks rank higher →

How Does SNN Rank in Medical Devices?

Among 157 Medical Devices stocks, SNN ranks #16 by Quality of Company score. CirclFi's QOC score of 8.7/10 evaluates 32 fundamental signals. A score of 8.7 places SNN in the top tier.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Smith & Nephew plc competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is SNN a Value Trap?

CirclFi's Value Trap algorithm assigns SNN a score of 7/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Smith & Nephew plc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Smith & Nephew plc's fundamental quality profile registers 8.7/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +220.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SNN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SNN's 9 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Smith & Nephew plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

EWEdwards Lifesciences CorporationQOC 8.7INMDInMode Ltd.QOC 8.5ESMCEscalon Medical Corp.QOC 8.7CNMDCONMED CorporationQOC 8.5TCMDTactile Systems Technology, Inc.QOC 8.8XTNTXtant Medical Holdings, Inc.QOC 8.4ATECAlphatec Holdings, Inc.QOC 6.9XAIRBeyond Air, Inc.QOC 5.8RBOTVicarious Surgical Inc.QOC 4.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: EW · INMD · ESMC · CNMD · TCMD · XTNT · ATEC · XAIR · RBOT · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to SNN?

7 companies across all industries closest to SNN’s Quality of Company score of 8.7/10.

UVSPUnivest Financial CorporationQOC 8.7SIGSignet Jewelers LimitedQOC 8.6IBMInternational Business Machines CorporationQOC 8.7IDTIDT CorporationQOC 8.6LEALear CorporationQOC 8.7EGPEastGroup Properties, Inc.QOC 8.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: UVSP · SIG · IBM · IDT · LEA · EGP · NVDA

Where Does SNN Sit in CirclFi's Medical Devices Rankings?

SNN is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Smith & Nephew plc’s Valuation?

What is Smith & Nephew plc's intrinsic value in 2026?

CirclFi puts Smith & Nephew plc (SNN)'s intrinsic value at $31.14 — the median of 9 independent model estimates as of 2026-08-27, ranging from $8.58 to $72.93. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $34.69 on its own. The Quality of Company score is 8.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SNN overvalued or undervalued right now?

At $29.13, 5 of 9 active models suggest SNN may be undervalued, while 4 indicate potential overvaluation. The median of all 9 fair value estimates is $31.14, within 6.9% of the current price of $29.13 — a consensus view that SNN is fairly valued. The assessment depends on which methodology best fits Smith & Nephew plc's business model in Medical Devices.

What does a Quality of Company score of 8.7 mean for SNN?

Smith & Nephew plc's QOC of 8.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SNN?

CirclFi analyzes SNN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SNN?

Of the 9 models currently active on SNN, Regime Cross-Sectional is the most bullish at $72.93 per share, and Markov DDM is the most bearish at $8.58. CirclFi's published fair value for SNN is the median of that range, $31.14, not either extreme. The gap between the two ends equals 207% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is SNN a value trap in 2026?

Smith & Nephew plc's Value Trap score is 7/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 9-model valuation engine, Smith & Nephew plc (SNN) has a median fair value of $31.14 — within 6.9% of the current price of $29.13 — as of 2026-08-27.” Source: circlfi.com/stock/SNN/ · Methodology
Primary sources for this SNN valuation
  • Financial statements: Smith & Nephew plc 10-K and 10-Q filings on SEC EDGAR (CIK 0000845982) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SNN as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on SNN.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

5 models hidden for SNN Unlock All 9 — $39/mo